Technical Analysis for AQST - Aquestive Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Historical AQST trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 1.81% | |
| Wide Bands | Range Expansion | 1.81% | |
| Wide Bands | Range Expansion | -0.59% | |
| Overbought Stochastic | Strength | -0.59% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Up 2% | about 5 hours ago | |
| 10 DMA Support | about 10 hours ago | |
| Down 1% | about 10 hours ago | |
| Up 1% | about 10 hours ago | |
| 10 DMA Support | 1 day ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/02/2020
- Sector: Healthcare
- Industry: Biotechnology
Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on the development of treatments for diseases related to the central nervous system (CNS). Its CNS programs consist of a pipeline of products that include Libervant, Sympazan, and AQST-117. Libervant is a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures. Sympazan is an oral soluble film formulation of clobazam for the treatment of seizures associated with a rare, intractable form of epilepsy known as Lennox-Gastaut Syndrome. AQST-117 is an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The Company’s complex molecule programs consist of AQST-108, and AQST-305, for the treatment of anaphylaxis and neuroendocrine tumors respectively. The Company also has a pipeline of products under partner programs, which includes Suboxone and APL-130277 for the treatment of opioid dependence, and Parkinson’s disease.
Pharmaceutical Diseases Drugs Psychoactive Drugs Epilepsy Chloroarenes Amyotrophic Lateral Sclerosis Opioids Lactams Gabaa Receptor Positive Allosteric Modulators Parkinson’s Disease Neuroendocrine Tumors Riluzole
Pharmaceutical Diseases Drugs Psychoactive Drugs Epilepsy Chloroarenes Amyotrophic Lateral Sclerosis Opioids Lactams Gabaa Receptor Positive Allosteric Modulators Parkinson’s Disease Neuroendocrine Tumors Riluzole
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 10.0 |
| 52 Week Low | 1.41 |
| Average Volume | 932,964 |
| 200-Day Moving Average | 5.15 |
| 50-Day Moving Average | 5.86 |
| 20-Day Moving Average | 6.01 |
| 10-Day Moving Average | 6.54 |
| Average True Range | 0.47 |
| ADX | 21.23 |
| +DI | 27.75 |
| -DI | 17.28 |
| Chandelier Exit (Long, 3 ATRs ) | 6.00 |
| Chandelier Exit (Short, 3 ATRs ) | 6.05 |
| Upper Bollinger Band | 7.36 |
| Lower Bollinger Band | 4.65 |
| Percent B (%b) | 0.77 |
| BandWidth | 45.10 |
| MACD Line | 0.32 |
| MACD Signal Line | 0.22 |
| MACD Histogram | 0.096 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 7.15 | ||||
| Resistance 3 (R3) | 7.11 | 6.95 | 7.08 | ||
| Resistance 2 (R2) | 6.95 | 6.84 | 6.96 | 7.05 | |
| Resistance 1 (R1) | 6.84 | 6.78 | 6.90 | 6.88 | 7.03 |
| Pivot Point | 6.68 | 6.68 | 6.70 | 6.69 | 6.68 |
| Support 1 (S1) | 6.57 | 6.57 | 6.63 | 6.61 | 6.45 |
| Support 2 (S2) | 6.41 | 6.51 | 6.42 | 6.43 | |
| Support 3 (S3) | 6.30 | 6.41 | 6.40 | ||
| Support 4 (S4) | 6.34 |
